ESMO Lung Cancer 2022 – Noemi Reguart
Noemi Reguart outlines if EGFR-directed treatment in the setting of advanced NSCLC should be based on T790M monitoring in clinical practice, outlines recent insights gained in the negative CANOPY-A trail using the anti-IL-1β antibody canakinumab after resection of early-stage NSCLC and summarizes the current treatment landscape in Europe with respect to small-cell lung cancer.
Here is the full ESMO 2022 Lung Cancer report.
More posts
Ovarian cancer: taking PARP inhibition one step further
Ovarian cancer: taking PARP inhibition one step further Individualized dosing o
Getting innovation from the laboratories into clinical practice
Getting innovation from the laboratories into clinical practice Andrés Cervantes
Milestones of PD-1 inhibition in gastric and esophageal cancer
Milestones of PD-1 inhibition in gastric and esophageal cancer Gastric cancer,
Preface – ESMO 2020 Solid Tumors
Preface – ESMO 2020 Solid Tumors Ronan Kelly, MD, MBA – Director of the